Core Insights - Neuralink, founded by Elon Musk, is planning a significant expansion in its business model, aiming to treat diseases and explore the human brain in unprecedented ways. The company projects to implant chips in 20,000 patients annually by 2031, generating at least $1 billion in annual revenue [1]. Group 1: Business Expansion Plans - The company plans to operate approximately five large clinics over the next six years and launch at least three versions of its implant devices, including "Telepathy" for brain-machine communication, "Blindsight" to help the blind regain vision, and "Deep" for treating tremors and Parkinson's disease [1]. - By 2029, Neuralink expects its "Telepathy" device to receive U.S. regulatory approval, with plans for 2,000 surgeries per year, generating at least $100 million in annual revenue. By 2030, the "Blindsight" chip is projected to be in use, increasing annual surgeries to 10,000 and annual revenue to over $500 million [2]. Group 2: Financial Projections and Funding - The revenue forecasts are based on a conservative charge of $50,000 per surgery. Neuralink has raised $1.3 billion in funding, with a current valuation of $9 billion [2]. - The company has garnered significant attention and investment due to the medical application potential of brain-machine interface technologies, although no permanent human-implant devices have been approved by U.S. regulatory authorities yet [2]. Group 3: Clinical Trials and Technological Developments - Currently, fewer than 10 participants are involved in clinical trials, and no patients have yet regained vision or treated Parkinson's disease through this technology [1]. - In clinical trials, paralyzed patients have been able to control computers using Neuralink devices for activities such as browsing the internet, gaming, and video editing. The company is also testing visual implant devices on monkeys [2].